Douglas Lane & Associates LLC Trims Stake in UnitedHealth Group Incorporated $UNH

Douglas Lane & Associates LLC trimmed its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH) by 9.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 67,715 shares of the healthcare conglomerate’s stock after selling 6,956 shares during the quarter. Douglas Lane & Associates LLC’s holdings in UnitedHealth Group were worth $24,857,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Vilga Financial Planning LLC increased its position in UnitedHealth Group by 3.5% in the 3rd quarter. Vilga Financial Planning LLC now owns 882 shares of the healthcare conglomerate’s stock worth $324,000 after purchasing an additional 30 shares during the last quarter. Breakwater Capital Group boosted its stake in shares of UnitedHealth Group by 14.6% in the 3rd quarter. Breakwater Capital Group now owns 2,229 shares of the healthcare conglomerate’s stock valued at $818,000 after purchasing an additional 284 shares in the last quarter. LifeGoal Investments LLC acquired a new stake in shares of UnitedHealth Group during the 3rd quarter worth about $212,000. Emergent Wealth Advisors LLC bought a new stake in UnitedHealth Group during the third quarter worth about $226,000. Finally, Stableford Capital II LLC grew its position in UnitedHealth Group by 83.2% during the 3rd quarter. Stableford Capital II LLC now owns 4,374 shares of the healthcare conglomerate’s stock worth $1,606,000 after acquiring an additional 1,986 shares during the last quarter. 87.86% of the stock is currently owned by institutional investors and hedge funds.

UnitedHealth Group Trading Up 1.9%

UNH traded up $7.07 during trading on Friday, reaching $378.02. 3,350,592 shares of the company’s stock were exchanged, compared to its average volume of 7,336,301. UnitedHealth Group Incorporated has a fifty-two week low of $255.96 and a fifty-two week high of $461.62. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 0.78. The firm has a market capitalization of $339.30 billion, a PE ratio of 24.34, a P/E/G ratio of 1.41 and a beta of 0.60. The company’s fifty day moving average price is $389.50 and its 200-day moving average price is $380.30.

UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings data on Thursday, July 16th. The healthcare conglomerate reported $6.38 EPS for the quarter, topping analysts’ consensus estimates of $4.94 by $1.44. UnitedHealth Group had a return on equity of 16.53% and a net margin of 3.14%.The business had revenue of $112.03 billion during the quarter, compared to analysts’ expectations of $110.81 billion. During the same period in the previous year, the firm earned $4.08 earnings per share. The firm’s quarterly revenue was up .4% compared to the same quarter last year. UnitedHealth Group has set its FY 2026 guidance at 19.500-20.000 EPS. As a group, equities analysts forecast that UnitedHealth Group Incorporated will post 19.85 EPS for the current year.

UnitedHealth Group Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 22nd. Shareholders of record on Monday, September 14th were issued a $2.32 dividend. This represents a $9.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, September 14th. UnitedHealth Group’s dividend payout ratio is 59.72%.

Key Stories Impacting UnitedHealth Group

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: UnitedHealth’s deliberate exit from unprofitable business lines is reportedly driving significant margin expansion despite relatively flat revenue and declining membership. Investors may see additional upside if management raises its 2026 outlook or confirms that the margin improvement is sustainable. The stock trades at roughly 16 times estimated 2027 earnings, below its historical five-year average, leaving room for a valuation re-rating. UnitedHealth: A Beat Is Priced In, But There’s Room For Surprise
• Positive Sentiment: Third-quarter results are scheduled for October 13, with analysts expecting earnings of approximately $4.12 to $4.15 per share on revenue near $111.4 billion. Forecast earnings growth of about 41% reflects expectations for cost control, restructuring benefits and improved medical-cost management. A beat or stronger outlook could provide a near-term catalyst. UnitedHealth Gears Up for Q3 Earnings
• Neutral Sentiment: Humana’s improved Medicare Advantage star ratings are reshaping the managed-care competitive landscape. UnitedHealth held steady in the comparison, suggesting no immediate company-specific impact, but the ratings reinforce the importance of benefit quality and enrollment execution. Humana Soars on Improved Medicare Advantage Star Ratings
• Negative Sentiment: TD Cowen lowered its price target for UnitedHealth to $402, signaling more limited near-term upside even though the target remains above recent trading levels. UnitedHealth Group Price Target Lowered to $402

Wall Street Analysts Forecast Growth

UNH has been the topic of a number of recent analyst reports. New Street Research set a $402.00 price objective on UnitedHealth Group in a research note on Friday. Robert W. Baird raised shares of UnitedHealth Group from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $287.00 to $453.00 in a report on Thursday, July 16th. Argus upped their target price on shares of UnitedHealth Group from $400.00 to $470.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Zacks Research lowered shares of UnitedHealth Group from a “strong-buy” rating to a “hold” rating in a report on Monday, September 14th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on UnitedHealth Group from $370.00 to $467.00 and gave the company a “hold” rating in a research report on Friday, July 17th. Twenty equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $462.59.

Insider Buying and Selling

In related news, CEO Patrick Conway sold 1,169 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $390.00, for a total value of $455,910.00. Following the sale, the chief executive officer directly owned 15,328 shares of the company’s stock, valued at approximately $5,977,920. The trade was a 7.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.19% of the company’s stock.

About UnitedHealth Group

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.